leisure time -WSS

leisure time

author：explore 2025-09-28 00:49:40 - browse：5

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： PEPFAR is under serious threat — and so is global health

WSS

STAT series 'Denied by AI' wins major journalism prizes

STAT reporters are Pulitzer Prize finalists for investigative reporting

How medical schools plan to diversify without affirmative action

Abbott's new stent may help patients with peripheral artery disease

Generate Biomedicines machine learning biotech raises $273M

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

knowledge

leisure time

focus

Guidelines to prevent youth baseball injuries need more muscle

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Hollywood unions extend contract negotiations for actors

What to make of Biden’s latest efforts on cancer research

What does generative AI mean for health care? We asked experts

Obesity drug from Roche shows promise in early study

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT reporters are Pulitzer Prize finalists for investigative reporting

How to save PrEP access — and even expand it

Boston hospital trains restaurant workers on naloxone for overdoses

focus

Private equity could exacerbate cardiology's overuse problem, experts fear

STAT reporters are Pulitzer Prize finalists for investigative reporting

Abbott's new stent may help patients with peripheral artery disease

Oak Street deal isn't the answer to health care's woes

Diverse clinical trials: Why aren’t we there yet?

WATCH: Why do bright lights make us see spots?

explore

hotspot

Wikipedia

focus